The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2
J Chin Med Assoc
; 2020.
Article
| WHO COVID | ID: covidwho-337012
ABSTRACT
Recently, the SARS-CoV-2 was quickly identified as the causal pathogen leading to the outbreak of severe acute respiratory syndrome-like illness all over the world. As the SARS-CoV-2 infection pandemic proceeds, many efforts are being dedicated to the development of diverse treatment strategies. Increasing evidence showed potential therapeutic agents directly acting against SARS-CoV-2 virus, such as interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking inhibitor. To date, several direct anti-SARS-CoV-2 agents have demonstrated promising in vitro and clinical efficacy. This article reviews the current and future development of direct acting agents against SARS-CoV-2.
Full text:
Available
Collection:
Databases of international organizations
Database:
WHO COVID
Journal:
J Chin Med Assoc
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS